Serine/threonine-protein kinase VRK2

Description:

Description
  • Accession: Q86Y07
  • Swissprot: VRK2_HUMAN
  • Organism: Homo sapiens
  • Gene: VRK2
  • Target class: Kinase

Drug Relations:

bosutinib
a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases Bioactivity details MOA
dasatinib
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. Bioactivity details MOA
ruxolitinib
a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19. Bioactivity details MOA